As of September 30, 2026, Siemens Healthineers AG carries a market capitalization of 47.96B, placing it among publicly traded companies globally. Its enterprise value stands at 45.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 47.96B |
| Enterprise Value | 45.67B |
Siemens Healthineers AG's next confirmed earnings release is scheduled for February 4, 2027.
| Earnings Date | 2/4/2027 |
As of September 30, 2026, Siemens Healthineers AG has 2.24B shares outstanding.
| Shares Outstanding | 2.24B |
As of September 30, 2026, Siemens Healthineers AG trades at a trailing price-to-earnings ratio of 19.11. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 2.13.
| PE Ratio | 19.11 |
| PS Ratio | 1.79 |
| PB Ratio | 2.13 |
| P/TBV Ratio | -10.32 |
| P/FCF Ratio | 17.29 |
| P/OCF Ratio | 12.86 |
As of September 30, 2026, Siemens Healthineers AG trades at an EV/EBITDA multiple of 9.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Siemens Healthineers AG trades at an EV/FCF ratio of 14.59, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 45.67B versus a market cap of 47.96B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.71 |
| EV / EBITDA | 9.19 |
| EV / EBIT | 12.61 |
| EV / FCF | 14.59 |
As of September 30, 2026, Siemens Healthineers AG maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.35, indicating elevated leverage, while an interest coverage ratio of 10.74 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.18 |
| Quick Ratio | 0.22 |
| Debt / Equity | 4.35 |
| Debt / EBITDA | 0.20 |
| Interest Coverage | 10.74 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 361,190.47 in revenue per employee across its workforce of 74,150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.37 indicates how many times Siemens Healthineers AG sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Revenue Per Employee | 361,190.47 |
| Employee Count | 74,150.00 |
| Inventory Turnover | 3.37 |
Over the twelve months ended September 30, 2026, Siemens Healthineers AG recorded 732.18M in income tax expense. That works out to an effective tax rate of 22.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.27B, leaving 2.51B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 732.18M |
| Effective Tax Rate | 22.36 |
As of the close on November 16, 2026, Siemens Healthineers AG's stock has declined approximately 5.21% over the past 52 weeks. The 50-day moving average sits at 22.76, while the 200-day moving average is 21.85.
| 52-Week Price Change | -5.21% |
| 50-Day Moving Average | 22.76 |
| 200-Day Moving Average | 21.85 |
Over the twelve months ended September 30, 2026, Siemens Healthineers AG generated 26.78B in revenue and converted that into 2.51B in net income, yielding earnings per share of 1.14. EBITDA reached 4.97B, while operating income came in at 3.62B.
| Revenue | 26.78B |
| Gross Profit | 10.33B |
| Operating Income | 3.62B |
| Pretax Income | 3.27B |
| Net Income | 2.51B |
| EBITDA | 4.97B |
| EBIT | 3.62B |
| Earnings Per Share (EPS) | 1.14 |
As of September 30, 2026, Siemens Healthineers AG holds 3.35B in cash and equivalents against 981.53M in total debt, resulting in a net debt position of -2.88B. Total book value stands at 22.50B, with working capital of 2.76B providing operational flexibility.
| Cash & Cash Equivalents | 3.35B |
| Total Debt | 981.53M |
| Net Debt | -2.88B |
| Equity (Book Value) | 22.50B |
| Book Value Per Share | 10.06 |
| Working Capital | 2.76B |
Siemens Healthineers AG produced 3.73B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -954.32M in capital expenditures, free cash flow totaled 2.77B - equivalent to 1.24 per share.
| Operating Cash Flow | 3.73B |
| Capital Expenditures | -954.32M |
| Free Cash Flow | 2.77B |
| FCF Per Share | 1.24 |
Over the twelve months ended September 30, 2026, Siemens Healthineers AG posted a gross margin of 38.57, reflecting its pricing power and cost economics. The operating margin of 13.53 and net profit margin of 9.37 provide insight into operational efficiency.
| Gross Margin | 38.57 |
| Operating Margin | 13.53 |
| Pretax Margin | 12.23 |
| Profit Margin | 9.37 |
| EBITDA Margin | 18.55 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 5.78, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.96, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Siemens Healthineers AG shareholders.
| Shareholder Yield | 4.96 |
| FCF Yield | 5.78 |
As of September 30, 2026, Siemens Healthineers AG has an Altman Z-Score of 2.85, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.85 |
Already premium?